Argenx sales expand as additional clinical and regulatory work advances

Argenx ($ARGX) reported third-quarter 2026 product sales of approximately $1.7 billion, an increase of 54% from a year earlier and 13% from the preceding quarter. Net profit attributable to shareholders increased to $506 million from $344 million. Continued commercial expansion of VYVGART supports the funding base for its autoimmune-disease development program.

The company reported a supplemental application for ocular myasthenia gravis and plans to submit its immune-mediated necrotizing myopathy application before year-end 2026. It also plans an additional registrational study in dermatomyositis following positive ALKIVIA results. Separately, a pediatric generalized myasthenia gravis application is under priority review, with a February 2027 decision target. These developments broaden potential future uses, but applications, trial plans and review deadlines are distinct from regulatory approvals and do not establish future commercial revenue.

Sources:

• GlobeNewswire